Could ePRO Be The New Standard In Health Reimbursement?

Developing innovative drugs takes time, with an average of 9.1 years between the first-in-human trial and regulatory approval.^[1] Early-stage trials average even longer at nearly a decade, so many companies do not consider their marketing and sales strategies. Recently, however, early-phase protocols have been collecting patient-reported outcomes (PROs) not only to get regulatory approval but to demonstrate value to public and private payers.